References
- Lehner KR, Baumann MH. Psychoactive ‘bath salts’: compounds, mechanisms, and toxicities. Neuropsychopharmacology 2013; 38: 243–244.
- Ross EA, Watson M, Goldberger B. “Baths salts” intoxication. N Engl J Med 2011; 365: 967–968.
- Fauquet JP, Morel E, Demarty C, Rapin JR. Role of central catecholamines in the psychostimulant activity of pyrovalerone. Arch Int Pharmacodyn Ther 1976; 224:325–337.
- Servin A, Fauquet JP, Jacquot C, Rapin JR. Effects of pyrovalerone on peripheral noradrenergic mechanisms. Biochem Pharmacol 1978; 27:1693–1694.
- Meltzer PC, Butler D, Deschamps JR, Madras BK. 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem 2006; 49: 1420–1432.
- Benzie F, Hekman K, Cameron L, Miller C, Smolinske S. Emergency department visits after use of a drug sold as “bath salts”. Morbidity and mortality weekly report 2011; 60:624–627.
- Warrick BJ, Hill M, Hekman K, Christensen R, Goetz R, Casavant MJ, et al. A 9-state analysis of designer stimulant, “bath salt,” hospital visits reported to poison control centers. Ann Emerg Med 2013; 62:244–251.
- Murray BL, Murphy CM, Beuhler MC. Death following recreational use of designer drug “bath salts” containing 3,4-methylenedioxypyrovalerone. J Med Toxicol 2012; 8:69–75.
- EMCDDA Annual report on the state of the drugs problem in Europe. Lisbon 2012. ISBN/ISSN: 1609-6150.
- OFDT 2012. Enquête 2009 SINTES Observation sur la composition des produits de synthèse. http://www.ofdt.fr/BDD/publications/docs/epfxemr4.pdf. Accessed September, 2013
- ANSM 2012. ADDENDUM au compte rendu de la Commission nationale des stupéfiants et des psychotropes du 16 juin 2011. http://ansm.sante.fr/var/ansm_site/storage/original/application/fb81dc38741cb1adda2423a26e0470b1.pdf. Accessed September, 2013.
- Legifrance 2012. Arrêté du 27 juillet 2012 modifiant les arrêtés du 22 février 1990 fixant la liste des substances classées comme stupéfiants et la liste des substances psychotropes. Legifrance. JORF n°0178 du2 août2012 page 12664, texte n°28. http://www.legifrance.gouv.fr/affichTexte.do?cidTexte = JORFTEXT00002624 6525&dateTexte = &categorieLien = id. Accessed September, 2013
- Sauer C, Peters FT, Haas C, Meyer MR, Fritschi G, Maurer HH. New dresigner drug α-pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J Mass Spectrom 2009; 44:952–964.
- Marinetti LJ, Antonides HM. Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results. J Anal Toxicol 2013; 37:135–146.
- Rosenbaum CD, Carreiro SP, Babu KM. Here today, gone tomorrow… and back again? A review of herbal marijuana alternatives (K2, spice), synthetic cathinones (bath salts), kratom, salvia divinorum, methoxetamine, and piperazines. J Med Toxicol 2012; 8:15–32.
- Brenneisen R, Fisch HU, Koelbing U, Geisshusler S, Kalix P. Amphetamine-like effects in humans of the khat alkaloid cathinone. Br J Clin Pharma 1990; 30:825–828.
- Aasebø W. ECG-voltage in alcoholics and non-alcoholics with acute alcohol intoxication. J Forensic Leg Med 2009; 16: 381–384.
- Singla S, Sachdeva R, Mehta JL. Cannabinoids and atherosclerotic coronary heart disease. Clin Cardiol 2012; 35:329–335.
- Ho-Sang S, Yun-Suk OS, Soha L, Byung-Bin P. Detection and identification of pyrovalerone and its hydroxylated metabolite in the rat. J Anal Toxicol 1996; 20:568–572.
- Wood DM, Davies S, Cummins A, Button J, Holt DW, Ramsey J, Dargan PI. Energy-1 (NRG-1): don't believe what the newspapers say about it being legal. Emerg Med J 2011; 28:1068–1070.
- Brandt SD, Freeman S, Sumnall HR, Measham F, Cole J. Analysis of NRG ‘legal highs’ in the UK: identification and formation of novel cathinones. Drug Test Anal 2011; 3:569–575.